Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Total Current Liabilities (2019 - 2025)

Pulmonx (LUNG) has disclosed Total Current Liabilities for 7 consecutive years, with $22.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 25.02% to $22.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.9 million, a 25.02% increase, with the full-year FY2024 number at $24.4 million, up 5.53% from a year prior.
  • Total Current Liabilities was $22.9 million for Q3 2025 at Pulmonx, up from $22.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $24.4 million in Q4 2024 to a low of $16.3 million in Q2 2021.
  • A 5-year average of $20.5 million and a median of $21.3 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 40.11% in 2021, then fell 2.39% in 2022.
  • Pulmonx's Total Current Liabilities stood at $17.6 million in 2021, then increased by 5.37% to $18.5 million in 2022, then increased by 25.23% to $23.2 million in 2023, then increased by 5.53% to $24.4 million in 2024, then decreased by 6.38% to $22.9 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Total Current Liabilities are $22.9 million (Q3 2025), $22.4 million (Q2 2025), and $24.4 million (Q4 2024).